Clinical trials: Rifampin
Tuberculosis, Pulmonary
Accuracy and Feasibility of Xpert Ultra
Consenting adults presenting with signs and symptoms compatible with pulmonary tuberculosis will be interviewed for demographic and medical information, and then will be asked to provide 3-4 expectorated sputum specimens.
- Trial name
- NCT03072576
- Testing
- Xpert MTB/RIF Ultra
- Where
- 6 sites in Belarus, Georgia and 2 more
- Volunteers
- 1,400 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Latent Tuberculosis Infection
Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection
The investigators aim to study the prevalence of adverse reactions of anti-tuberculosis (TB) drugs in latent tuberculosis infection (LTBI), and determine the risk factors of anti-TB drug-related toxicity in LTBI in Korean health…
- Trial name
- NCT03312647
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Hanyang University
Pulmonary Tuberculosis
Ultra-Short Regimen for Elderly DS-TB
Tuberculosis (TB) remains one of the leading global public health concerns and is among the top ten causes of death from a single infectious agent.
- Trial name
- Elderly-USR (NCT07076225)
- Testing
- Bedaquiline (B), Sitafloxacin (S), Linezolid (L)
- Volunteers
- 300 people
- Sponsor
- Shenzhen Third People's Hospital
HIV Infections, Tuberculosis
Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis
Triomune is the most commonly prescribed treatment for HIV infection in Uganda. Triomune is manufactured by a generic drug company and consists of three drugs combined in a single pill given twice daily (stavudine 30mg plus…
- Trial name
- NCT00617643
- Testing
- Nevirapine without dose escalation, Nevirapine initiation with dose escalation
- Where
- Uganda
- Volunteers
- 18 people
- Sponsor
- Makerere University
Healthy Volunteers
Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600
Study to Evaluate the Effect of Repeat-Dose Rifampin on the pharmacokinetics (PK) of PF-06651600.
- Trial name
- NCT04266509
- Testing
- PF-06651600, Rifampin
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Gastrointestinal Hormones
Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8
The purpose of this study is to evaluate the impact of genetic variants of OATP 1B3 or MRP 2 on the systemic disposition of endogenously formed CCK-8 and to determine the influence of a single-dose of the transporter inhibitor…
- Trial name
- NCT02507167
- Testing
- mixed meal, Rifampin
- Where
- Germany
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Parkinson's Disease
A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin
The purpose of this study is to investigate the effects of CYP3A4/5 inhibitor or inducer on the pharmacokinetics of KW-6356 when CYP3A4/5 inhibitor or inducer is orally administered to healthy Japanese men for 7 days.
- Trial name
- NCT04070495
- Testing
- KW-6356, Clarithromycin, Rifampicin
- Where
- Japan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Tuberculosis, Meningeal
Optimizing Treatment to Improve TBM Outcomes in Children
In this open-labeled, randomized clinical trial, the Investigator will assess the safety and pharmacokinetics (PK) of model-optimized doses of rifampicin (RIF) with or without levofloxacin (LEVO) given to children as part of…
- Trial name
- TBM-KIDS (NCT02958709)
- Testing
- High-dose: RIF, INH, PZA, EMB, High dose: RIF, INH, PZA, LEVO, Standard of care: RIF, INH, PZA, EMB
- Where
- 3 sites in India, Malawi
- Volunteers
- 38 people
- Sponsor
- Johns Hopkins University
Tuberculosis
Safety of doTBal® in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program
Phase IV, observational, cohort, prospective study. With duration according to the indicated scheme, 6 months of treatment (2 intensive months and 4 months of sotén) for pulmonary tuberculosis.
- Trial name
- NCT04916899
- Testing
- Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol
- Where
- Mexico
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
HIV Infections, Tuberculosis
Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)
Successful therapy of both tuberculosis and HIV disease share similar problems: pill burden, drug interaction, adherence challenge and toxicity.
- Trial name
- NCT00115609
- Testing
- efavirenz, tenofovir DF, emtricitabine
- Where
- France
- Volunteers
- 70 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Tuberculosis
PK Study of Anti-TB Drugs
This is a prospective descriptive and pharmacokinetic study will be conducted among newly diagnosed patients registered in the two SMRU TB clinics located on the Thai-Myanmar border.
- Trial name
- NCT02457208
- Testing
- Isoniazid (H), Rifampicin (R), Pyrazinamide (Z)
- Where
- Thailand
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pulmonary Tuberculosis
Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB
This study aims to find an optimized initial regimen for pulmonary tuberculosis(PTB), evaluating the efficacy, safety and acceptability of isoniazid, rifampicin and moxifloxacin(HRM) for the intensive phase of initial therapy of…
- Trial name
- NCT04187469
- Testing
- Moxifloxacin, Isoniazid, Rifampicin, Rifampicin,Isoniazid,Pyrazinamide,Ethambutol
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
HIV Infections, Tuberculosis
Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
A 48 week, randomized, open-label, two arm study to compare the efficacy, safety and tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1 infected patients started at 2-6 weeks after…
- Trial name
- NCT00476853
- Testing
- HAART containing nevirapine
- Where
- 6 sites in Thailand
- Volunteers
- 42 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Drug-drug Interaction, Autoimmune Diseases
Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers
This is a single-center, 2-part, non-randomized, open-label study of the drug-drug interactions of belumosudil (KD025) with itraconazole, rifampicin, rabeprazole, and omeprazole in healthy male subjects.
- Conditions
- Drug-drug Interaction, Autoimmune Diseases, Fibrotic Disease
- Trial name
- NCT03530995
- Testing
- Belumosudil, Itraconazole, Rabeprazole
- Where
- United Kingdom
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Kadmon Corporation, LLC
Staphylococcus Aureus Endocarditis, Prosthetic Valve Endocarditis
Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus
This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S.
- Trial name
- RIFA-SNAP (NCT07253688)
- Testing
- Rifampin, No rifampin
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Drug-resistant Tuberculosis, Pulmonary Tuberculosis
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
This is an investigational, prospective, multicenter, single-arm, open label trial. The goal of this clinical trial is to evaluate the efficacy and safety of a 6-month all-oral regimen, consisting of Bedaquiline (BDQ, B)…
- Conditions
- Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis
- Trial name
- INSPIRE-BDLL (NCT06649721)
- Testing
- bedaquiline, delamanid, linezolid
- Where
- 34 sites in China
- Volunteers
- 120 people
- Sponsor
- Huashan Hospital
Staphylococcal Infections
Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections
Clindamycin and rifampicin are authorized in osteoarticular infection treatment (IDSA guidelines) but some interaction is observed. The objective of this study is to evaluate and quantify rifampicin interaction on clindamycin
- Trial name
- DALARI (NCT02782078)
- Testing
- Clindamycin and rifampicin dosages
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Latent Tuberculosis, Staphylococcus Aureus
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus…
- Trial name
- NCT05073926
- Testing
- No intervention is part of the study protocol
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Skane
Non-Puerperal Mastitis
Ablation Versus Non-ablation Strategies for Non-puerperal Mastitis: A Prospective Real-world Registry Study
The goal of this prospective registry cohort study is to evaluate the efficacy and quality-of-life impact of ablation therapy in patients with non-puerperal mastitis.
- Trial name
- NCT07894614
- Testing
- Ablation, Observation
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Song Hongping
Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort
The goal of this clinical trial is to learn if the all-oral, shorter-course BLMZ regimen can treat Rifampicin-Resistant Tuberculosis (RR-TB) in Chinese participants aged 12 years and older.
- Conditions
- Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis, Drug-resistant Tuberculosis
- Trial name
- INSPIRE-BLMZ (NCT07268664)
- Testing
- BLMZ
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Beijing Chest Hospital